Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Michael R. Migden"'
Publikováno v:
Oncotarget
Although basal cell carcinoma (BCC) is often managed successfully with surgery, patients with locally advanced BCC (laBCC) or metastatic BCC (mBCC) who are not candidates for surgery or radiotherapy have limited treatment options. Most BCCs result fr
Autor:
Amy C. Moreno, Michael K. Wong, Randal S. Weber, Priyadharsini Nagarajan, Michael R. Migden, David I. Rosenthal, Bonnie S. Glisson, Renata Ferrarotto, Neil D. Gross, Avi Benov, Anshu Khanna, Jeffrey N. Myers, Ryan P. Goepfert, Guojun Li, Sameer Kini, Frederico Omar Netto Gleber, Samantha Tam, Adel K. El-Naggar, Moran Amit, Mohamed Aashiq, Chuan Liu
Publikováno v:
European Journal of Cancer. 144:169-177
Background The last revision of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual included a specific system for cutaneous squamous cell carcinoma (CSCC) of the head and neck. Here, we assessed the prognostic performance of six cand
Autor:
Randal S. Weber, Guojun Li, Samantha Tam, Bonnie S. Glisson, Jeffrey N. Myers, Chuan Liu, Sameer Kini, Mohamed Aashiq, Neil D. Gross, Moran Amit, Avi Benov, Michael K. Wong, Anshu Khanna, Adel K. El-Naggar, Priyadharsini Nagarajan, Ryan P. Goepfert, Frederico O. Gleber-Netto, Amy C. Moreno, Renata Ferrarotto, Michael R. Migden, David I. Rosenthal, Erez N. Baruch
Publikováno v:
Cancer. 127:1238-1245
Background The prognostic performance of the recently updated American Joint Committee on Cancer lymph node classification of cutaneous head and neck squamous cell carcinoma (HNSCC) has not been validated. The objective of this study was to assess th
Autor:
Wanxing Chai-Ho, Jenny H. Lee, Ignacio Melero, Andrew Haydon, Nikhil I. Khushalani, Jose Lutzky, Andrew F. Hill, Gregory A. Daniels, Muhammad Alamgeer, Ragini R. Kudchadkar, Dimitrios Colevas, Ann Silk, Piyush Sheladia, Daniel Brungs, Shui He, Praveen K. Bommareddy, Frances A. Collichio, Samantha Bowyer, Céleste Lebbé, Michael R. Migden, Danny Rischin, Jean-jaques Grob, Matthew G. Fury, Claudia Andreu-Vieyra
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundThe prognosis for advanced and metastatic cutaneous squamous cell carcinoma (CSCC) remains poor for many patients with the disease despite approval of the anti-PD1 antibodies cemiplimab and pembrolizumab.1 2 RP1 is an oncolytic virus (HSV-1
Autor:
Sherrif F. Ibrahim, Benedetta Campanelli, Morganna Freeman, Medha Sasane, Sunandana Chandra, Michael L. Andria, Guilherme Rabinowits, Emily S. Ruiz, Jigar Desai, Nikhil I. Khushalani, Alex Seluzhytsky, Zhen Chen, Chieh I. Chen, Michael R. Migden
Publikováno v:
Future Oncology. 16:11-19
In 2018, cemiplimab-rwlc became the first systemic treatment approved by the US FDA for patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. In 2
Publikováno v:
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 47(11)
Publikováno v:
Future oncology (London, England). 17(35)
Locally advanced or metastatic cutaneous squamous cell carcinoma no longer amenable to surgical resection or primary radiation therapy requires an alternative approach to treatment. Until 2018, management consisted of limited systemic chemotherapies,
Autor:
Matthew G. Fury, Siyu Li, Medha Sasane, Dirk Schadendorf, Nikhil I. Khushalani, Karl D. Lewis, Vera Mastey, Elizabeth Stankevich, Axel Hauschild, Jocelyn Booth, Michael R. Migden, Anne Lynn S. Chang, Suk Young Yoo, Chieh I. Chen, Leonel Hernandez-Aya, Emmanuel Okoye, Zhen Chen, Chrysalyne D. Schmults, Israel Lowy, Alexander Guminski, Brett G.M. Hughes, Danny Rischin, Alesha A. Thai, Annette M. Lim
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
BackgroundTo provide pooled longer term data from three groups of a phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC), and to determine duration of response (DOR) and impact on quality of life (QoL).Method
Autor:
Olivia M. Chen, Keemberly Kim, Chelsea Steele, Kelly M. Wilmas, Nader Aboul-Fettouh, Carrick Burns, Hung Quoc Doan, Sirunya Silapunt, Michael R. Migden
Publikováno v:
Cancers. 14:3720
Basal cell carcinoma (BCC), the most common cancer in humans, is a malignant neoplasm of cells derived from the basal layer of the epidermis. Tumor characteristics such as histologic subtype, primary versus recurrent tumor, anatomic location, size, a
Autor:
Carrick Burns, Shelby Kubicki, Quoc-Bao Nguyen, Nader Aboul-Fettouh, Kelly M. Wilmas, Olivia M. Chen, Hung Quoc Doan, Sirunya Silapunt, Michael R. Migden
Publikováno v:
Cancers. 14:3653
cSCC is increasing in prevalence due to increased lifespans and improvements in survival for conditions that increase the risk of cSCC. The absolute mortality of cSCC exceeds melanoma in the United States and approaches that of melanoma worldwide. Th